Navigation Links
Lacosamide validated as promising therapy for uncontrolled partial-onset seizures
Date:2/25/2010

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients. Researchers from the Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Thomas Jefferson University Medical School, Arkansas Epilepsy Program, Schwarz Biosciences and Johns Hopkins University Hospital conducted this study which is available early online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

Epilepsy is one of the most common neurologic disorders, affecting up to 2% of the worldwide population according to the Centers for Disease Control and Prevention (CDC). More than half of the total epilepsy population experience POS, or focal seizures, which occur in one part of the brain. While several anti-epileptic drugs have entered the market in the past decade, approximately 30% of patients with epilepsy experience recurrent seizures and undesirable side effects from their medication. There remains a significant unmet need for well-tolerated medications able to provide adequate seizure control. Lacosamide is emerging as a promising candidate to reduce seizure frequency and severity with few adverse effects.

The efficacy and safety of adjunctive lacosamide for POS was established in three multicenter, randomized, double-blind, placebo-controlled trials. Results of the first trial indicated that study participants taking 400 and 600 mg/day of lacosamide experienced significantly larger reductions in seizure frequency and significantly greater responder rates compared with placebo. Two additional phase III trials were conducted in parallel to confirm these results.

Steve Chung, M.D., and colleagues report the results of the second phase III trial, which was conducte
'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V)
2. New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings
3. Inventor of Newly Available Vimpat(R) (lacosamide) C-V Meets a Woman Who Experienced Greater Seizure Control With Use of This New Antiepileptic Drug
4. UCB Announces FDA Filing for lacosamide in the Treatment of Partial Onset Seizures in Adults with Epilepsy
5. UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
6. iCardiac's Highly Automated QT(sm) Technology Cross-Validated Against Results from Five Leading ECG Core Laboratories
7. Heart failure risk model validated
8. BioMosaics Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer
9. Life Line Screening Data on Peripheral Arterial Disease Validated
10. iCardiac's Highly Automated QT(sm) Technology Now Validated in Over 10 Clinical QT Studies
11. Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Yisrayl Hawkins, Pastor at The House ... in light of the Ferguson, Missouri unrest. Yisrayl starts his ... and explains why it has only increased. , He ... created. He says there is a very specific reason for ... there is a set of rules, or Laws that if ...
(Date:12/26/2014)... 26, 2014 Plugin and template developers from ... 5 Plugin for Final Cut Pro X. , “TransPack Volume ... tool to pull off an industry professional look” Said Christina ... hands on TransPack Volume 5, a new level of professionalism ... set of over 50 Final Cut Pro X transitions featuring ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 India Network ... insurance in the USA, announced today a new version ... members in choosing the right plan for their visiting ... complexity out of the selection process when choosing an ... age group with only a few clicks. Many elderly ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a comprehensive high-tech ... marketing of a series of induction heating equipment. Today, ... of induction brazing equipments . , According to ... refers to the joining of two or more ... manager says that there are fundamental differences in the ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4
... moderate eczema sufferers who are looking for a cost-effective ... a prescription now have a new option to consider. ... the Journal of Cosmetic Dermatology finds ... for its effective, yet gentle, moisturizing, makeup-removing properties), is ...
... Rochelle, NY, March 9, 2009Chemicals present in cranberriesand not ... bacteria from attaching to the cells that line the ... Journal of Medicinal Food , a peer-reviewed journal ... The article is available free online at www.liebertpub.com/jmf ...
... More Than 20 YearsIRVINE, Calif., March 9 ... today announced that the European Commission has formally granted ... the treatment of patients with non-metastatic, resectable osteosarcoma, a ... children and young adults. The Centralized marketing authorization ...
... results from FREEDOM study show continued, significant relief ... higher rates of hospitalization and death among ESRD ... (Nasdaq: NXTM ), a leading manufacturer ... interim results from its ongoing FREEDOM study, which ...
... in 5 lawsuits nationally aimed at stopping hospitals from ... Nurses today applauded the announcement of a ... between bedside nurses and Northeast Health, a network which ... contends that Albany area hospitals had for years violated ...
... company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), ... Journal of Human Hypertension . The advance online publication of ... study will also be published in the May issue of ... RESPeRATEthe only medical device cleared by the FDA and CE-approved ...
Cached Medicine News:Health News:Commonly used beauty staple clinically proven to help treat eczema 2Health News:Commonly used beauty staple clinically proven to help treat eczema 3Health News:New research reveals how cranberry products prevent urinary tract infections 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 2Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 3Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 4Health News:IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma 5Health News:NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year 2Health News:NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year 3Health News:NxStage Reports Sustained Reduction in Clinical Depressive Symptoms for Daily Home Hemodialysis Patients After One Year 4Health News:In the Midst of a National Nurse Shortage Crisis ... Nurses Celebrate Landmark Legal Settlement That Will Help Ensure Fair Compensation & Bring More RNs to the Bedside 2Health News:In the Midst of a National Nurse Shortage Crisis ... Nurses Celebrate Landmark Legal Settlement That Will Help Ensure Fair Compensation & Bring More RNs to the Bedside 3Health News:New published study demonstrates over-the-counter device lowers blood pressure in diabetic patients 2
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical Isotope ... engaged primarily in the development of brachytherapy devices ... today announced that it has filed a ... Drug Administration ("FDA") for marketing clearance for its ... of the U.S. Food, Drug and Cosmetic Act ...
(Date:12/24/2014)... Dec. 23, 2014   Assurex Health, a ... to healthcare providers for behavioral health and chronic ... $30 million in equity financing from new and ... , President and Chief Executive Officer. ... development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... 29 FUJIFILM Medical Systems USA, Inc. is pleased to ... at the 2009 Radiological Society of North America (RSNA) Annual ... an innovative new technology to provide clinicians with Fujifilm,s trademark ... a smart way for users to transition to DR without ...
... Nov. 28 Siemens Healthcare redefines productivity with a ... technology and with its new Dot(TM) (Day optimizing throughput) engine. ... Aera* 1.5 Tesla (T) and the new MAGNETOM Skyra* 3T ... the Radiological Society of North America (RSNA) from November 29 ...
Cached Medicine Technology:FUJIFILM's DR Cassette Makes World Debut 2Siemens Introduces Its New Power Couple at RSNA 2009 2Siemens Introduces Its New Power Couple at RSNA 2009 3Siemens Introduces Its New Power Couple at RSNA 2009 4Siemens Introduces Its New Power Couple at RSNA 2009 5Siemens Introduces Its New Power Couple at RSNA 2009 6Siemens Introduces Its New Power Couple at RSNA 2009 7
Kit for the Preparation of Technetium Tc 99m Sestamibi for injection...
Straight Tip, Measures from 0mm to 20mm in 1mm Increments, Readable on Both Sides, Thumbscrew Lock Holds Desired Setting; in Titanium....
Very fine, blunt tip....
... The e.cam duet Signature Series ... and PET FDG imaging applications. The system ... capability with the features and flexibility of ... in one unit.,The e.cam duet ...
Medicine Products: